ImmunoGen

ImmunoGen, Inc. is a clinical-stage biotechnology company based in Waltham, Massachusetts, specializing in the development of antibody-drug conjugate (ADC) therapies for cancer treatment. The company employs its Targeted Antibody Payload technology to create products that deliver potent cytotoxic agents directly to tumor cells. Notable product candidates include mirvetuximab soravtansine, currently in Phase III clinical trials for platinum-resistant ovarian cancer, and IMGN632, which is in Phase I trials for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Additionally, ImmunoGen's preclinical programs feature investigational ADCs such as IMGC936, co-developed with MacroGenics. The company has established collaborations with numerous pharmaceutical firms, enhancing its research and development capabilities. Founded in 1980, ImmunoGen continues to focus on advancing innovative therapies to improve cancer treatment outcomes.